NCT03499483View on ClinicalTrials.gov

Biktarvy for Non-Occupational Post-Exposure Prophylaxis (nPEP)

PHASE4CompletedINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

January 24, 2019

Primary Completion Date

March 30, 2020

Study Completion Date

March 31, 2020

Conditions
HIV Prevention
Interventions
DRUG

bictegravir

Single One Pill Formulation of bictegravir, emtricitabine/tenofovir alafenamide (Bictarvy) to be taken once daily orally for a period of 28 days.

Trial Locations (1)

02215

Fenway Community Health, Boston

All Listed Sponsors
lead

Fenway Community Health

OTHER

NCT03499483 - Biktarvy for Non-Occupational Post-Exposure Prophylaxis (nPEP) | Biotech Hunter | Biotech Hunter